Second-generation epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer

Expert Opinion on Investigational Drugs

Volumn 18, Issue 3, 2009, Pages 293-301

  Mukherji, Deborah ^b   Spicer, James ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

AEE788; BIBW 2992; CI 1033; EGFR inhibitors; EKB 569; Epidermal growth factor receptor; Erlotinib; Gefitinib; HKI 272; Lapatinib; Non small cell lung cancer; PF 299804; Tyrosine kinase inhibitors; Vandetanib; XL647

Indexed keywords

4 [3 CHLORO 4 (2 PYRIDINYLMETHOXY)ANILINO] 3 CYANO 6 (4 DIMETHYLAMINOCROTONAMIDO) 7 ETHOXYQUINOLINE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; BIBW 2992; CANERTINIB; CARBOPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; LAPATINIB; NERATINIB; PACLITAXEL; PELITINIB; PF 299804; PLACEBO; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VANDETANIB; XL 647; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLOOD TOXICITY; CLINICAL TRIAL; DIARRHEA; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EGFR GENE; ENZYME ACTIVITY; ENZYME INHIBITION; FATIGUE; GENE; GENE MUTATION; HUMAN; HYPOTENSION; LUNG INTERSTITIUM; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; QT PROLONGATION; RASH; REVIEW; SIDE EFFECT; SKIN TOXICITY; SURVIVAL RATE; TREATMENT RESPONSE; DRUG ANTAGONISM; DRUG DEVELOPMENT; ENZYMOLOGY; LUNG TUMOR; METABOLISM;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG DISCOVERY; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 67449088116     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780902762843     Document Type: Review

References (59)

1. Olayioye MA, Neve RM, Lane HA, et al. The ErbB signaling network receptor heterodimerization in development and cancer. EMBO J 2000;19:3159-3167 (Pubitemid 30428195)
2. Yarden Y, Sliwkowski MX. Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2001;2:127-137
3. Berger MS, Gullick WJ, Geenfield C, et al. Epidermal growth factor receptors in lung tumours. J Pathol 1987;152:297-307 (Pubitemid 17124234)
4. Dazzi H, Hastleton PS, Thatcher N, et al. Expression of epidermal growth factor receptor (EGFR) in human lung tumours. Br J Cancer 1986;54:746-749
5. Wheatley-Price P, Shepherd FA. Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes. Curr Opin Oncol 2008;20:162-175 (Pubitemid 351317404)
6. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 2005;250:2129-2140
7. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor mutations in lung cancer. Nat Rev Cancer 2007;7:169-181 (Pubitemid 46316032)
8. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-346 (Pubitemid 40425952)
9. Cox G, Vyberg M, Melgaard B, et al. Herceptest: HER2 expression and gene amplification in non-small cell lung cancer. Int J Cancer 2001;92:480-483 (Pubitemid 32319419)
10. Hirsch FR, Franklin WA, Veve R, et al. HER2/neu expression in malignant lung tumours. Semin Oncol 2002;29:51-58 (Pubitemid 34226519)
11. Nakumura H, Kawasaki N, Taguchi M, Kabasawa K. Association of HER2 overexpression with prognosis in non-small cell lung cancer: a meta-analysis. Cancer 2005;103:1865-1873 (Pubitemid 40563259)
12. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 2005;353:123-132 (Pubitemid 41058344)
13. Fukoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trials of gefitinib for previously treated patients with advanced non-small cell lung cancer (the IDEAL-1 Trial). J Clin Oncol 2003;21:2237-2246 (Pubitemid 46621858)
14. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-2158 (Pubitemid 37432975)
15. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomized, placebo-controlled, multi-centre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-1537 (Pubitemid 41540110)
16. Chang A, Parikh P, Thongprasert S, et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer; subset analysis from the ISEL study. J Thorac Oncol 2006;1:847-855 (Pubitemid 47181391)
17. Douillard JY, Kim E, Hirsh V, et al. Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-small cell lung cancer pretreated with platinum-based chemotherapy: a randomized, open-label Phase III study (INTEREST): PRS-02. J Thorac Oncol 2007;2:S305-06
18. Asahina H, Yamazaki K, Kinoshita I, et al. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 2006;95:998-1004 (Pubitemid 44606825)
19. Paz-Ares L, Sanchez JM, Garcia-Velasco A, et al. A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor [abstract 7020]. J Clin Oncol 2006;24
20. Jackman DM, Yeap BY, Sequist LV, et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 2006;12:3908-3914 (Pubitemid 44078074)
21. Riely GJ, Pao W, Pham D, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006;12:839-844 (Pubitemid 43259866)
22. Balak MN, Gong Y, Riely GJ, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006;12:6494-6501 (Pubitemid 44799723)
23. Bean J, Brennan C, Shih JH, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007;104:20932-20937
24. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small cell lung cancer to gefitinib. N Engl J Med 2005;352:786-792 (Pubitemid 40271173)
25. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling, Sciencexpress. Science 2007;316:1039-1043 (Pubitemid 46799492)
26. Fong T, Morgensztern D, Ramaswamy G. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer. J Thorac Oncol 2008;3:303-310 (Pubitemid 351654331)
27. Mok T, Wu YL, Thongprasert S, et al. Phase III, randomized, open-label, first-line study of gefitinib (G) vs carboplatin/ paclitaxel (C/P) in clinically selected patients with advanced non-small cell lung cancer (NSCLC) (IPASS) [abstract LBA2]. Ann Oncol 2008;1 (Suppl 8)
28. Maheswaran S, Sequist LV, Nagrath S, et al. Detection of mutations in EGFR in circulating lung-cancer cells. NEJM 2008;359:366-377
29. Erlichman C, Hidalgo M, Boni JP, et al. Phase 1 study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumours. J Clin Oncol 2006;24:2252-2260 (Pubitemid 46630654)
30. Yoshimura N, Kudoh S, Kimura T, et al. EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib. Lung Cancer 2006;51:363-368 (Pubitemid 43265820)
31. Rabindran SK, Discafani CM, Rosfjord EC, et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 2004;64:3958-3965 (Pubitemid 38697310)
32. Kwak EL, Sordella R, Bell DW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 2005;102:7665-7670 (Pubitemid 40741028)
33. Wong KK, Fracasso PM, Bukowski RM, et al. HKI-272, an irreversible pan erbB receptor tyrosine kinase inhibitor: preliminary phase 1 results in patients with solid tumors. J Clin Oncol 2006;24:3018
34. Wong KK. HKI-272 in non-small cell lung cancer. Clin Cancer Res 2007;13:4593s-596s
35. Allen LF, Eisman IA, Fry DW, et al. CI-1033, an irreversible pan-ErbB receptor inhibitor and its potential application for the treatment of breast cancer. Semin Oncol 2003;30 (Suppl 16):65-78 (Pubitemid 37433398)
36. Calvo E, Tolcher AW, Hammond LA, et al. Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day in, 7-day off schedule: a phase 1 pharmacokinetic and food effect study. Clin Cancer Res 2004;10:7112-7120 (Pubitemid 39487694)
37. Neumantis J, Eiseman I, Cunningham C, et al. Phase 1 clinical and pharmacokinetic evaluation of CI-1033 in patients with refractory cancer. Clin Cancer Res 2005;11:3846-3853 (Pubitemid 40685605)
38. Zinner RG, Neumantis J, Eiseman I, et al. Phase 1 clinical and pharmacodynamic evaluation of CI-1033 in patients with refractory cancer. Clin Cancer Res 2007;13:3006-3014 (Pubitemid 46849577)
39. Simon GR, Garrett CR, Olson SC, et al. Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor. Results of a phase 1 pharmacokinetic study. Clin Cancer Res 2006;12:4645-4651
40. Shin D, Nemunaitis J, Zinner RG, et al. A phase I clinical and biomarker study of CI-1033, a novel pan-erbB tyrosine kinase inhibitor in patients with solid tumors [abstract 324]. Proc Am Soc Clin Oncol 2001;20:82a
41. Garland LL, Hidalgo M, Mendelson DS, et al. A phase 1 clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumours. Clin Cancer Res 2006;12:4274-4282 (Pubitemid 44453347)
42. Chiappori AA, Ellis PM, Hann JT, et al. A phase 1 evaluation of oral CI-1033 in combination with paclitaxel and carboplatin as first-line chemotherapy in patients with advanced non-small cell lung cancer. J Thorac Oncol 2006;1:1010-1019 (Pubitemid 47181371)
43. Janne PA, von Pawel J, Cohen RB, et al. Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non-small-cell lung cancer. J Clin Oncol 2007;25:3936-3944 (Pubitemid 47477271)
44. Shaw H, Plummer R, Vidal L, et al. A phase 1 dose escalation study of BIBW2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in patients with advanced solid tumours [abstract 3027]. J Clin Oncol 2006;23:18S
45. Spicer J, Calvert H, Vidal L, et al. Activity of BIBW2992, an oral irreversible dual kinase inhibitor, in non-small cell lung cancer (NSCLC) with mutated EGFR: D7-02 [abstract]. J Thorac Oncol 2002;2:S410
46. Spicer J, Harris D, Ang J, et al. A phase 1 study of daily BIBW2992, an irreversible EGFR/HER2 dual kinase inhibitor, in combination with weekly paclitaxel [abstract 474P]. Ann Oncol 2008;19(Suppl 8):viii-157
47. Marshall J, Shapiro GI, Terlizzi E, et al. A phase 1 dose escalation trial of BIBW2992, an irreversible EGFR/HER2 kinase inhibitor, for 20 and 13 days in combination with docetaxel every 21 day [abstract 475P]. Ann Oncol 2008;19 (Suppl 8): viii-158
48. Yang C, Shih J, Chao C, et al. Use of BIBW 2992, a novel irreversible EGFR/HER2 TKI, to induce regression in patients with adenocarcinoma of the lung and activating EGFR mutations: preliminary results of a single-arm phase II clinical trial [abstract 8026]. J Clin Oncol 2008;26
49. Hoekstra R, Dumez H, Eskens F. Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. Clin Cancer Res 2006;11:6908-6915
50. Smylie M, Blumenschein GR, Dowlati A, et al. A phase II multicenter trial comparing two schedules of lapatinib (LAP) as first or second line monotherapy in subjects with advanced or metastatic non-small cell lung cancer (NSCLC) with either bronchioalveolar carcinoma (BAC) or no smoking history [abstract 7611]. J Clin Oncol 2007;25
51. Janne PA, Schellens JH, Engleman JA, et al. Preliminary activity and safety results from a phase I clinical trial of PF-00299804, an irreversible pan- HER inhibitor, in patients (pts) with NSCLC [abstract 8027]. J Clin Oncol 26:2008;20 (Suppl)
52. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis and tumor growth following oral administration. Cancer Res 2002;62:4645-4655 (Pubitemid 34898591)
53. Holden SN, Eckhardt SG, Basser R, et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumours. Ann Oncol 2005;16:1391-1397 (Pubitemid 41158486)
54. Natale R, Bodkin D, Govindan B, et al. ZD6474 versus gefitinib in patients with advanced NSCLC: final results from a two-part, double-blind, randomized phase II trial [abstract 7000]. J Clin Oncol 2006;24
55. Heymach JV, Paz-arez L, De-braud F, et al. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2008 : published online, doi:10.1200/JCO.2008.17.3138
56. Arnold MA, Seymour L, Smylie M, et al. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy. J Clin Oncol 2007;25:4278-4284
57. Waklee HA, Adeji AA, Halsey J, et al. A phase 1 dose-escalation and pharmacokinetic (PK) study of a novel spectrum selective kinase inhibitor, XL647, in patients with advanced solid malignancies [abstract 3044]. J Clin Oncol 2006;24
58. Rizvi N, Kris MG, Miller V, et al. A Phase II study of XL647 in non-small cell lung cancer (NSCLC) patients enriched for presence of EGFR mutations. J Thorac Oncol 2007;2:S737
59. Baselga J, Rojo F, Dumez H, et al. Phase 1 study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: a pharmacokinetic (PK)-pharmacodynamic (PD) study to identify the optimal therapeutic dose regime [abstract 3028]. J Clin Oncol 2005;23